First-line Disease Modifying Treatments in Pediatric-onset Multiple Sclerosis in Greece: Therapy Initiation at More Advanced Age is the Main Cause of Treatment Failure, in a Retrospective Observational Study, with a Cohort from a Single Multiple...

Overview

Journal Neurol Sci

Specialty Neurology

Date 2022 Oct 5

PMID 36197577

Authors

Charalampos Skarlis

Nikolaos Markoglou

Maria Gontika

Anastasia Bougea

Serafeim Katsavos

Artemios Artemiadis

George Chrousos

Marinos Dalakas

Leonidas Stefanis

Maria Anagnostouli

Affiliations

Soon will be listed here.

Abstract

Objectives: Long-term immunomodulatory therapy of pediatric onset-multiple sclerosis (POMS) is based mainly on published case series and internationally agreed guidelines. Relevant studies in the Greek population are absent from the literature. The purpose of this study is to present data on the efficacy and safety of the 1st line immunomodulatory drugs in the treatment of POMS patients.

Materials And Methods: The present study included 27 patients meeting the IPMSSG criteria for POMS and who are monitored at the outpatient clinic of the Multiple Sclerosis and Demyelinating Diseases Unit (MSDDU), of the 1st Neurological Department, University Hospital of Aeginition. All patients received 1st line immunomodulatory drugs as initial therapy. Clinical, laboratory, and imaging parameters of the disease were recorded before and after treatment.

Results: Post-treatment, a significant reduction of the relapse number (mean ± SD: 2.0 ± 1.0 vs 1.2 ± 1.6, p = 0.002), EDSS progression (mean ± SD: 1.5 ± 0.8 vs 0.9 ± 0.7, p = 0.005) and ARR (mean ± SD: 1.5 ± 0.7 vs 0.4 ± 0.5, p = 0.0001) was observed, while no changes were observed in the EDSS score, (mean ± SD: 1.8 ± 0.6 vs 1.9. 0.6, p = 0.60). Advanced age at treatment initiation increased the risk for drug discontinuation before 24 months of therapy (HR = 0.6, 95% CI (0.35-0.99), p = 0.04).

Conclusions: Most pediatric patients are forced to switch to either more efficacious 1st line or 2nd line drugs. Additionally, our study suggests that older age at the time of the 1st line treatment initiation, contributes to earlier drug discontinuation.

Citing Articles

The impact of HLA-DRB1 alleles in a Hellenic, Pediatric-Onset Multiple Sclerosis cohort: Implications on clinical and neuroimaging profile.

Skarlis C, Markoglou N, Gontika M, Artemiadis A, Pons M, Stefanis L Neurol Sci. 2024; 45(11):5405-5411.

PMID: 38819529 DOI: 10.1007/s10072-024-07619-0.

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis.

Puthenparampil M, Gaggiola M, Miscioscia A, Mauceri V, De Napoli F, Zanotelli G Ther Adv Neurol Disord. 2023; 16:17562864231177196.

PMID: 37808246 PMC: 10559704. DOI: 10.1177/17562864231177196.

Multiple Sclerosis and MEN2 Neoplasia in a Female Patient: A Unique Co-Existence with Expanded Immunological Interest and Therapeutical Challenges, before and after Patient's COVID-19 Infection.

Markoglou N, Simeakis G, Alevizaki M, Velonakis G, Chatzistamatiou T, Spyropoulou-Vlachou M Biomedicines. 2022; 10(11).

PMID: 36359367 PMC: 9687925. DOI: 10.3390/biomedicines10112850.

References

Krysko K, Graves J, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G . Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Ann Neurol. 2020; 88(1):42-55. DOI: 10.1002/ana.25737. View

Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S . Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). Pediatr Neurol. 2018; 83:19-24. DOI: 10.1016/j.pediatrneurol.2018.03.007. View

Bartels F, Nobis K, Cooper G, Wendel E, Cleaveland R, Bajer-Kornek B . Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure. Mult Scler. 2019; 25(7):927-936. DOI: 10.1177/1352458519829698. View

Wallach A, Waltz M, Casper T, Aaen G, Belman A, Benson L . Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Mult Scler. 2019; 26(14):1938-1947. DOI: 10.1177/1352458519891984. View

Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M . Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003; 34(3):120-6. DOI: 10.1055/s-2003-41274. View

Makhani N, Ngan B, Kamath B, Yeh E . Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS. Neurology. 2013; 81(9):850-2. PMC: 3908464. DOI: 10.1212/WNL.0b013e3182a2cc4a. View

Chitnis T, Ghezzi A, Bajer-Kornek B, Boyko A, Giovannoni G, Pohl D . Pediatric multiple sclerosis: Escalation and emerging treatments. Neurology. 2016; 87(9 Suppl 2):S103-9. DOI: 10.1212/WNL.0000000000002884. View

Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, Blaschek A, Valis M, Aaen G . Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis. Front Neurol. 2021; 11:606418. PMC: 7812971. DOI: 10.3389/fneur.2020.606418. View

Chitnis T, Aaen G, Belman A, Benson L, Gorman M, Goyal M . Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain. 2020; 143(9):2733-2741. DOI: 10.1093/brain/awaa199. View

10.

Wassmer E, Chitnis T, Pohl D, Amato M, Banwell B, Ghezzi A . International Pediatric MS Study Group Global Members Symposium report. Neurology. 2016; 87(9 Suppl 2):S110-6. PMC: 10688073. DOI: 10.1212/WNL.0000000000002880. View

11.

Macaron G, Feng J, Moodley M, Rensel M . Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. Curr Treat Options Neurol. 2019; 21(10):50. DOI: 10.1007/s11940-019-0592-z. View

12.

McKay K, Hillert J, Manouchehrinia A . Long-term disability progression of pediatric-onset multiple sclerosis. Neurology. 2019; 92(24):e2764-e2773. PMC: 6598792. DOI: 10.1212/WNL.0000000000007647. View

13.

Chitnis T, Banwell B, Kappos L, Arnold D, Gucuyener K, Deiva K . Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021; 20(12):1001-1011. DOI: 10.1016/S1474-4422(21)00364-1. View

14.

Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P . Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Mult Scler. 2018; 25(3):399-407. DOI: 10.1177/1352458518754364. View

15.

Skarlis C, Anagnostouli M . The role of melatonin in Multiple Sclerosis. Neurol Sci. 2019; 41(4):769-781. DOI: 10.1007/s10072-019-04137-2. View

16.

Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B . Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007; 356(25):2603-13. DOI: 10.1056/NEJMoa067597. View

17.

Ghezzi A, Amato M, Annovazzi P, Capobianco M, Gallo P, La Mantia L . Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009; 30(3):193-9. DOI: 10.1007/s10072-009-0083-1. View

18.

Gontika M, Anagnostouli M . Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses. Mult Scler Int. 2019; 2018:8487471. PMC: 6282147. DOI: 10.1155/2018/8487471. View

19.

Sawcer S, Franklin R, Ban M . Multiple sclerosis genetics. Lancet Neurol. 2014; 13(7):700-9. DOI: 10.1016/S1474-4422(14)70041-9. View

20.

De Silvestri A, Capittini C, Mallucci G, Bergamaschi R, Rebuffi C, Pasi A . The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Dis Markers. 2019; 2019:1409069. PMC: 6875418. DOI: 10.1155/2019/1409069. View